Background and objective: Standard surgical management for early stage lung cancer is lobectomy with mediastinal lymph node dissection. The feasibility of limited resection remains controversial; we retrospectively assessed lung cancer-specific survival (LCSS) and overall survival (OS) in early stage non-small cell lung cancer (NSCLC) to evaluate whether segmentectomy is comparable to standard lobectomy. Methods: Patients with primary NSCLC of 20 mm or less who were diagnosed from 2000 to 2014 were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. To compare the two surgical interventions, a propensity score analysis was performed between lobectomy and segmentectomy. Results: Of the 15 358 patients analysed, there were 14 549 lobectomies and 809 segmentectomies. The 5-year OS was 76% for the lobectomy group and 74.4% for the segmentectomy group. There were no significant differences in OS or LCSS among patients who underwent lobectomy versus segmentectomy, as demonstrated by the propensity-matched hazard ratio (HR) for OS (HR: 1.195, 95% CI: 0.993-1.439) and LCSS (HR: 1.124, 95% CI: 0.860-1.469). The inverse propensity-weighted analysis also supported these results. Segmentectomy was more likely to be performed in elderly patients. In the subset of patients aged ≥75 years, the segmentectomy group demonstrated comparable OS (HR: 1.17, 95% CI: 0.87-1.58, P = 0.31) and LCSS (HR: 0.94, 95% CI: 0.59-1.51, P = 0.81), compared with the lobectomy group. Conclusion: Equivalent OS and LCSS were demonstrated in patients with primary NSCLC of 20 mm or less without lymph node or distant metastasis.
INTRODUCTION
Since 1960, the main surgical treatment for early resectable lung cancer has been lobectomy along with mediastinal lymph node dissection.
1,2 Although anatomical segmentectomy allows for standard mediastinal lymph node dissection, along with better preserved pulmonary function, pulmonary resection less than lobectomy is still controversial in clinical practice. 1, 3 Therefore, sublobar resections have tended to be used as a second-line option for 'compromised' patients who have multiple co-morbidities anticipated to impair surgical and post-operative morbidity. 4 Previous observational studies have reported conflicting results on segmentectomy, largely owing to different definitions, combinations of operations, data enrolment periods and outcome assessments. 5 A Surveillance, Epidemiology, and End Results (SEER) data analysis of patients with non-small cell lung cancer (NSCLC) of ≤1 cm who were diagnosed between 1988 and 2005 demonstrated equivalent overall survival (OS) after segmentectomy. 6 The same database was used to assess population between 2000 and 2012 and yielded poorer OS and lung cancer-specific survival (LCSS) in patients with NSCLC of <2 cm who underwent a segmentectomy. 7 A recent meta-analysis of stage I NSCLC demonstrated non-inferior OS for segmentectomy compared with lobectomy. 8 However, another large data analysis of early NSCLC using the National Cancer Database demonstrated poorer OS for segmentectomy (hazard ratio (HR): 1.7, 95% CI: 1.29-2.26, P < 0.001) compared with lobectomy. 9 The population demographic of lung cancer is evolving, with increasing numbers of more elderly patients with many co-morbidities being diagnosed and undergoing surgical treatment. 10 Furthermore, the diagnostic work up, surgical techniques and management of patients are improving; this has improved survival over the last decades, as indicated in a time series analysis study that showed a decreasing survival benefit with lobectomy compared with segmentectomy. 5 Therefore, the OS and LCSS for patients who have undergone surgery in more recent times need to be reviewed.
The objective of this study is to assess the OS and LCSS between lobectomy and segmentectomy in primary NSCLC of ≤20 mm and lung cancer staged N0/M0 from the SEER database.
METHODS

Patient selection
Patients were selected from the SEER programme, sponsored by the National Cancer Institute, which contains epidemiological, pathological and survival data of all cancer cases in 18 areas of the United States since 1972. The SEER population is highly representative in terms of geography, socio-economic status, race, ethnicity and age. SEER*Stat 8.3.4 (http://www.seer.cancer.gov) was used to extract data for patients aged 18 years and older with early NSCLC from 2000 to 2014. Patients were primarily identified through 'SEER site Recode' using the term 'Lung and Bronchus' (C34.0 to C34.3, C34.8, C34.9) and through 'Behavior recode analysis' using the term 'Malignant'. The variable, 'Type of Reporting Source', was used to exclude the data from Figure 1 Study flow chart, with counts and reasons of exclusion from the data set. NSCLC, nonsmall cell lung cancer; RT, radiotherapy.
which the source comes from 'Autopsy only', 'Death certificate only', or 'Nursing/convalescent home/hospice'. For histopathology, the histological type international classification of disease for oncology-3 was used to derive the initial code. To restrict the data set for non-small cell carcinoma, we excluded small cell carcinoma and large cell neuroendocrine carcinoma.
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Patients were excluded if they were administered chemotherapy or radiotherapy or if their operation information was unknown. Details on the data cleansing process are shown in Figure 1 .
The following additional patient characteristics were extracted from the data set: age, sex, race, tumour size, the total number of excised lymph nodes, tumour pathology and grade, tumour location and cause of death.
Statistical analysis
The primary outcomes of this study were LCSS and OS, measured in months. Patients who were alive at the last available follow-up date in SEER were rightcensored at this date in the survival analysis.
Characteristics are summarized using conventional statistics, such as mean AE SD or median for continuous variables, and frequencies and percentages for categorical variables. The distribution for continuous variables was analysed by using the Student's t-test or Mann-Whitney U-test depending on the result of the Shapiro-Wilk test of normality. Categorical variables were compared using chi-square test or Fisher's exact test. The Kaplan-Meier method was used to obtain OS and LCSS for unmatched groups, and a log-rank test was used to compare survival curves between lobectomy and segmentectomy.
Given the observational nature of the SEER database, surgical allocation was not randomly assigned for the study population; therefore, we used a propensity score (PS) to balance pretreatment variables to establish the marginal causal effects of surgical choices. Variables included in the PS model were selected from the available baseline variables based on known associations with surgical choice and/or study outcomes: age at diagnosis, sex, race, tumour location, laterality of the lesion, mass size, diagnostic method (cytological or Figure 2 Overall (A; P = 0.054) and lung cancer-specific survivals (B; P = 0.63) for patients who underwent either lobectomy ( ) or segmentectomy ( ) before matching. P-value indicates a log-rank test.
histological diagnosis) and the total number of lymph nodes resected. We created a 1:1 matched sample by matching patients who underwent lobectomy and segmentectomy using calliper width equal to 0.2 of the SD for the logit of the PS and without replacement. To assess the balance of covariates between the two groups and after PS matching, mean standardized difference (MSD) was used. A mean SD of <0.10 was considered to support the assumption of balance between groups.
As for a second approach, PS model construction relied on the generalized boosted model, and then weight was extracted from the model to calculate the inverse probability of treatment weighting (IPTW). 12, 13 This method has been shown to outperform a simple logistic regression in the context of case-mix adjustment. 14, 15 The weight derived from PS was also applied to each case to produce an 'average treatment among the treated (ATT)' estimate. 16 The ATT was used instead of the 'average treatment effect (ATE)' option to allow for unavoidable selection of surgical patients and for coherence with PS matching.
Survival was plotted with a Kaplan-Meier curve for unmatched population, and Cox proportional hazards (PH) models were used to estimate the association between surgical types and OS or LCSS in the 1:1 matched sample, and IPTW-adjusted and IPTWweighted samples. We tested the assumption of proportionality of hazards using the Shoenfeld test. 
RESULTS
Characteristics of the study groups
After data purification, a total of 15 358 records were identified in the SEER cancer registry during the study period 2000-2014: 14 549 records were lobectomies and 809 were segmentectomies (Fig. S1 , Supplementary Information). The median follow-up time for the entire cohort was 56 months (interquartile range (IQR): 25-95 months). Overall, 10 454 (68.1%) of the patients were alive at the end of the study period (November 2015). Baseline characteristics are reported in Table 1 . Segmentectomies are more likely to be performed in the elderly, female patients, small tumour size, leftsided and lower lobe lesions. A larger number of lymph nodes were likely to be resected from the lobectomy patients.
The overall 5-year survival was 76.0% (95% CI: 75.2-76.8) in the lobectomy group and 74.4% (95% CI: 67.7-75.4) in the segmentectomy group. The 5-year LCSS was 86.0% (95% CI: 85.4-86.7) for the lobectomy group, and 84.7% (95% CI: 81.6-88.0) for the segmentectomy group. The survival analysis by log-rank test demonstrated the trend of a slightly Segmentectomy in early lung cancer lower OS in the segmentectomy group (P = 0.054) but no differences in LCSS between the unmatched two groups (P = 0.63) (Fig. 2) .
Survival analysis after matching
The distribution of MSD showed that all covariates were well balanced between the two groups after matching (Table 1 , Fig. S2 (Supplementary Information) ). All MSD shown are <0.10; matching was clearly effective in controlling covariate imbalance. In addition, the distributions of the PS were balanced between the two groups (Fig. 3) . Using Cox PH analysis in the matched sample, we could not identify a difference in OS and LCSS between two groups ( Table 2 , Fig. 4 ).
Survival analysis using the IPTW method
A drawback of PS matching is the exclusion of many control or treatment groups. In this study, we included all patients who underwent segmentectomy for matching, but the majority of patients who underwent lobectomy were excluded from matching. To handle this problem and to solidify the PS analysis, we adopted the IPTW approach. Both IPTW-adjusted model and IPTWweighted Cox model showed comparable OS and LCSS between the segmentectomy and lobectomy groups ( Table 2) . 
Additional analysis
DISCUSSION
The landmark study by the Lung Cancer Study Group was the only randomized controlled trial (RCT) to compare limited resection and lobectomy, and failed to demonstrate efficacy for limited resection in the treatment of T1N0 lung cancer patients. 2 This study included both segmentectomy and wide-wedge resection within the same 'limited resection' group that hindered proper evaluation of the treatment effect of segmentectomy. Despite this limitation, the result of this RCT indicated that lobectomy was the treatment of choice for T1N0 NSCLC. To our knowledge, there have been no RCT assessing the feasibility and oncological outcome of segmentectomy. Currently, there are several promising ongoing RCT by the JCOG group, including a phase III RCT studying segmentectomy versus lobectomy (JCOG0802/WJOG4607L) and a non-randomized confirmatory trial (JCOG1211) testing the efficacy of segmentectomy for clinical T1a-b N0 lung cancers with ground-glass opacities (GGO). 17, 18 In addition, a new trial has started comparing segmentectomy or wedge resection versus lobectomy for patients with 20 mm peripheral lung nodules on preoperative computed tomography scans (CALGB-140503, NCT 00499330; ClinicalTrials.gov). 19 These large RCT and nonrandomized trials will help determine whether segmentectomy could be the new standard for early lung cancer.
To date, there are many observational studies with combinations of different definitions, operation choices, target disease groups and analysis methods, and as a result, pros and cons exist regarding the role of segmentectomy. The SEER database has also been analysed mainly for stage IA NSCLC, and researchers have reported different conclusions even though those papers stemmed from the same SEER database. For example, Kates et al. reported non-inferior OS for segmentectomy with NSCLC of ≤1 cm, but the results of Dai et al. showed poorer OS after a segmentectomy for NSCLC lesions of ≤1 and 1-2 cm. 6, 7 The time periods of the two studies were different: between 1988 and 2005 for the former study and between 2000 and 2014 for the latter one. The patient enrolment period for the present study (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) largely overlapped with that of the latter study. Although their study was performed well in terms of comparing three procedures at the same time, there were some differences. We excluded patients who received chemotherapy during the early stage for unknown reasons. They also excluded patients ATT, average treatment among the treated; HR, hazard ratio; IPTW, inverse probability of treatment weighting; OS, overall survival; PS, propensity score. who were administered radiation, but there was no information about chemotherapy. Moreover, we excluded patients who were recommended to have either radiation or brain radiation after surgery, who had separate tumour nodules, who did not receive pathological lymph node examination and whose data source included only a nursing hospital or hospice. More importantly, the study by Dai et al. did not consider pretreatment covariate imbalance that could have influenced the treatment allocation and primary outcome accordingly. The study cohort appeared to be similar; however, as shown in Table 1 , critical covariates including age, sex and mass size, as well as the number of lymph nodes excised were different. As this would increase the level of bias and affected the result, we designed our study to evaluate only the effect of segmentectomy versus lobectomy after balancing factors related to the treatment allocation. 15 We presume this may have led to a different conclusion.
To reflect the recently observed trend in the population characteristics, we set the study period as after 2000. Importantly, in the SEER data set, the coding for segmentectomy, as well as detailed information of surgical procedure, is available from the data enrolled after 1998. There is potentially a concern regarding less lymph node dissection during segmentectomy than lobectomy, thus the staging in segmentectomy cases could be less precise, missing early metastases related to poorer survival. 9, 20 To avoid this potential problem, we restricted the sample to both pathological and clinical N0.
To verify the result of 1:1 matching, we used another advanced statistical method, the IPTW approach, and both the IPTW-weighted and IPTW-adjusted approaches confirmed our findings. IPTW approach has the benefit of balancing covariates using the entire study population. Our result is supported by other recent studies. A recent meta-analysis demonstrated comparable OS for segmentectomy, as compared with the lobectomy. 8 A further meta-analysis demonstrated that overall diseasefree survival for the 'intentional' segmentectomy group was not significantly different to lobectomy groups in early lung cancer. 21 Additionally, we explored the impact of age on survival after segmentectomy. From the matched data set, we extracted those patients aged over 75 years. A Cox PH showed equivalent OS and LCSS for both surgical options. Several studies showed comparable results to those of our study. In a study of patients older than 80 years, limited resection had comparable 5-year survival to that of lobectomy (58.8% vs 59.4%, respectively). 22 Another study also demonstrated no differences between segmentectomy and lobectomy in locoregional recurrences (6% vs 4%, respectively) or OS (49.8% vs 45.5%) in patients with stage I NSCLC older than 75 years. 23 Although there was no information regarding co-morbidities, in-hospital morbidity/mortality and recurrence in the SEER data base, the oncological outcomes did not hinder choosing segmentectomy in this age group.
One of the limitations of the SEER database is lack of information on the reason for segmentectomy ('intentional segmentectomy' or 'compromised segmentectomy'), detailed tumour characteristics and comorbidities. In addition, there is no information about progression-free survival. Although a higher locoregional recurrence after segmentectomy that may lead to a poorer outcome has been reported, a progression-free survival analysis was impossible in this study. 24 For intentional segmentectomy, disease-free survival was not significantly different from that of lobectomy (HR: 0.80, 95% CI: 0.50-1.30, P = 0.37) in a meta-analysis. 21 This study showed comparable LCSS, and LCSS can be assumed to be an indirect extension of progression-free survival. Moreover, as certain co-morbidities could have affected the choice of procedure, bias may have affected the analysis. This is another reason for choosing PS analysis; although a PS analysis may not be a panacea, it can better handle the covariate imbalance. Finally, because there were no data about preoperative or post-operative pulmonary function, we were not able to estimate the quality of life that could have been another benefit of segmentectomy over lobectomy at a population level.
In conclusion, segmentectomy for the treatment of small-sized ≤20 mm early NSCLC had OS and LCSS that were not significantly different from those of a lobectomy. A slightly lower OS was observed in the segmentectomy group, but this may represent a non-cancer-related death.
